Summary
- There are no clinical trials of canakinumab in patients with gout attacks refractory to several prior treatments.
- Adverse effects mainly include infections, hypersensitivity reactions and dizziness.
Full text available for free download.
©Prescrire 1 July 2014
"Canakinumab for gout attacks. Too risky" Prescrire Int 2014; 23 (151): 178. (Pdf, free).